rambazole for acne and psoriasis

Written by on September 20, 2005 in Acne Treatments with 2 Comments

Barrier Therapeutics is developing a class of drugs called based so-called RAMBA (Retinoic Acid Metabolic Blocking Agent) molecules.

Rambazole is still in development, having recently reported results in Phase 2a trials for the oral formulation for moderate to severe acne and measuring biological activity for the topical formulation. Their aim is to develop an oral formulation of Rambazole for the treatment of psoriasis and severe acne, as well as a topical formulation for psoriasis, acne, and wrinkles.

From Barrier Therapeutics Development Pipeline

Rambazole is our second product candidate based on the RAMBA class of molecules. We are developing an oral formulation of Rambazole for the treatment of psoriasis and severe acne and a topical formulation for dermatological indications, including common forms of acne and mild to moderate psoriasis. Preclinical studies suggest that Rambazole is more selective and more active than first generation RAMBA-based product candidates, such as Liarozole.

Oral Rambazole – We are currently conducting two Phase 2a clinical trials using oral Rambazole, one in moderate to severe psoriasis and the other in moderate to severe nodular acne. A review of initial Phase 2a trial data from 10 patients with moderate to severe psoriasis demonstrated a reduction in the psoriasis area severity index, commonly known as PASI score, by an average of 50% in patients treated with 1 mg once daily for eight consecutive weeks. These PASI scores were measured at week 10, two weeks after stopping the treatment. Based on these data in mid-2005, we plan to submit an IND or its European equivalent necessary for us to commence Phase 2b clinical trials of oral Rambazole for psoriasis.

Further Reading:

Read more about: Acne Treatments

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

2 Reader Comments

  1. alice says:

    Spanning the globe from Holland to Japan to New Zealand, clinical research over three decades finally reveals that psoriasis is not an incurable skin disease.

    Rather as reported in the British Journal of Dermatology, psoriasis is indeed a metabolic defect arising out of the inability of your cells to produce a key compound called fumaric acid.
    81% of the patients in the clinical studies, experienced total disappearance of the skin condition via supplementation by fumaric acid.

  2. Flávio José Silva de Almeida says:

    Tenho 45 anos e sofro bastante com a Iquitiose Vulgar. Li um comentário de uma uzuária que o Rambazole seria o medicamento via oral que causa menos e
    efeitos colaterais em vista de outros. O ocorrido foi em 2006. E desde então a ansiedade não passa. !! Vocês têm previsão de quando será lançado no brasil.

    Obrigado !

    Belo Horizonte , 25 de julho de 2001

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.